Overview

Study of Tesevatinib in Subjects With Non-Small Cell Lung Cancer, EGFR Activating Mutation, Prior Treatment With a Tyrosine Kinase Inhibitor, and Brain Metastases or Leptomeningeal Metastases

Status:
Completed

Trial end date:
2019-01-17

Target enrollment:

Participant gender:

Summary

A study to assess the activity of tesevatinib in subjects with NSCLC and activating EGFR mutations who have disease progression with Brain Metastases (BM) or Leptomeningeal Metastases (LM) or who heave either BM or LM at initial presentation.

Phase:

Phase 2

Details

Lead Sponsor:

Kadmon Corporation, LLC

Treatments:

XL647